Susan Groshen
University of Southern California
447 Papers
6.8K Citations
Susan Groshen is an academic researcher from University of Southern California. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 97, co-authored 434 publications. Previous affiliations of Susan Groshen include University of Pennsylvania.
Chat about Author
Papers
Microtransplantation: HLA-Mismatched Allogeneic Cellular Therapy of Acute Myeloid Leukemia (HMMACT)
Ann Mohrbacher,Ibrahim Syed,Noah M. Merin,Giridharan Ramsingh,Susan Groshen,Preet M. Chaudhary +5 more
TL;DR: Although there were the usual significant complications of treating leukemia and infections, the cellular therapy itself was well-tolerated and may reflect elimination of allogeneic cells by the patient’s immune system.
3
Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC).
Tanya B. Dorff,Susan Groshen,David I. Quinn,Amir Goldkorn,Cynthia L. Martel,Jacek Pinski,Peter Kuhn,Mitchell E. Gross +7 more
TL;DR: This work hypothesized that the combination of abiraterone plus dasatinib would delay the time to disease progression in mCRPC, and combined at full doses in a phase I trial without dose-limiting toxicity.
3
A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors
Syma Iqbal,Heinz-Josef Lenz,David R. Gandara,Stephen Shibata,Susan Groshen,Timothy W. Synold,Edward M. Newman +6 more
TL;DR: The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m2 preceded by escalating doses of docetaxel 60 mg /m2 administered every 3 weeks.
OC-14 - Baseline D-dimer levels are predictive of recurrent venous thromboembolism (VTE) at 6 months in cancer patients with VTE treated with tinzaparin.
Caroline I. Piatek,Scott T. Tagawa,D. Wei-Tsai,D. Hanna,Ilene C. Weitz,Casey O'Connell,Leanne Rochanda,Susan Groshen,Howard A. Liebman +8 more
TL;DR: In patients with active cancer and VTE treated with tinzaparin, baseline D-dimer levels above the median value were predictive of VTE recurrence at 6 months, and in patients who received ≥1 dose, plasma biomarkers were not predictive of OS.
3